Our next step: Proteolytic enzymes and the lymphatic system
Lymphatics regulate interstitial fluid balance, macromolecule clearance, and immune cell trafficking. In lymphedema and lymphatic dysfunction, protein-rich interstitial fluid, fibrin/fibrinogen fragments, and ECM remodeling (collagens, fibronectin, hyaluronan) increase tissue viscosity and impede flow. Proteolysis is a plausible lever to modify the local protein milieu and reduce resistance to lymph uptake and transport—but it must be precise to avoid harming lymphatic endothelium (LECs) and valves. That’s why the trypsin + chymotrypsin pair (with defined, orthogonal specificities) is the mechanistic centre, while papain/bromelain may serve as broader cysteine-protease complements. Clinical evaluations in preparation.
Our next step: Proteolytic enzymes and intimate hygiene
Protein-rich secretions and exudates support microbial adhesion and biofilm scaffolding. Serine proteases (trypsin + chymotrypsin) hydrolyze proteinaceous deposits and adhesins, potentially easing mechanical removal. Separately, chlorhexidine (CHX) is a well-established antiseptic; multiple in-vitro models (non-gynecologic) report enhanced biofilm disruption when a protease step precedes or accompanies CHX, consistent with matrix opening that improves antiseptic access.
Our next step: Proteolytic enzymes in topical applications
Chronic wounds often accumulate protein-rich exudate, fibrin slough, denatured ECM, and proteinaceous biofilm matrix, which increase local viscosity, hinder diffusion, and irritate peri-wound skin. Controlled proteolysis is a plausible lever to reduce this protein burden and loosen matrix—directly on the wound bed to ease gentle cleansing, and indirectly on the peri-wound to improve local hygiene and the microclimate associated with healthy microcirculation. Exposure must be precise in dose and time to avoid over-digestion of viable tissue, preserve granulation and the epidermal barrier, and protect capillary integrity. The trypsin + chymotrypsin pair (with defined, orthogonal specificities) remains the mechanistic centre.
Our next step: Microbial production pipe-line
Microbial production represents a promising next step in the evolution of proteolytic enzymes. Compared with traditional animal- or plant-derived sourcing, microbial systems offer the potential for tighter process control, defined fermentation conditions, improved batch-to-batch consistency, and scalable production under well-characterised manufacturing parameters. From a biochemical and technological perspective, this opens the way to more precisely tailored protease profiles, cleaner downstream processing, and even more transparent control over activity, purity, and stability.
For enzyme-based products, production origin is never a neutral variable. It influences not only yield, but also the comparability, reproducibility, and analytical definition of the final material. A microbial production pipeline therefore offers a particularly attractive framework for future enzyme development: one in which protease identity, activity, and processing conditions can be controlled from the earliest stage of production through to final release. For Wald Biotech, this is not simply a manufacturing question, but part of a broader commitment to precision, traceability, and next-generation enzyme technology.
